… ProQR Update August 2022 Announced today (August 11, 2022), ProQR will focus exclusively on the development of the … from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 …
… Building an Inclusive ProQR At ProQR we strive to create an inclusive culture where everyone … logo to incorporate the pride rainbow flag. Pride month at ProQR is an opportunity to celebrate and thank all of the …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
In June we caught up with our Lead Talent Acquisition, Silvia Catellani, to talk about ProQR, Pride, and driving an inclusive culture for present and future ProQRians.
… ProQR at TIDES to highlight our Axiomer® technology This month several ProQRians will attend the Oligonucleotide and Peptide … beyond. At this year’s TIDES Europe, Gerard Platenburg, ProQR Chief Scientific Officer, and co-founder, is presenting …
… Today marks an expansion of the ProQR and Lilly partnership In September 2021 ProQR announced a global licensing and research collaboration … originally announced in September 2021 , applied ProQR’s proprietary Axiomer® RNA editing platform to target …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
